FemmenessencePRO PERI is the first natural product to demonstrate, in published clinical trials, statistically significant effects on hormones in peri-menopausal women.
However FemmenessencePRO PERI does not introduce any hormones into the body, rather it nourishes the Hypothalamus Pituitary Adrenal Axis (HPA Axis), supporting the body’s own hormone production.
In clinical trials, 72-84% of post-menopausal women using FemmenessencePRO PERI experienced a highly statistically significant reduction in menopausal symptoms within 2 days to 8 weeks, with an average of 3 weeks.
By truly impacting hormone levels in peri-menopausal women, FemmenessencePRO PERI addresses the root cause of many health issues, not just the symptoms. Comprehensively impacting many different aspects of health and supporting foundational health.
Clinical trial results included:
- Supports hormone balance*
- Supports adrenal hormones and energy levels*
- Reduces hot flashes and night sweats*
- Supports libido, sexual health and vaginal dryness*
- Supports mood and an improved outlook on life*
- Supports mental health*
- Supports healthy body weight*
- Supports healthy cholesterol & triglyceride levels within normal ranges*
There are 13 different phenotypes of maca that are different colors, different DNA, contain different ingredient profiles and elicit different physiological effects. FemmenessencePRO PERI contains MacaLife® – a highly concentrated, certified organic proprietary combination of specific maca (Lepidium peruvianum)phenotypes, for women’s hormone balance. MacaLife® contains Maca-GO® and a proprietary combination of other maca phenotypes specifically to address peri-menopausal symptoms. MacaLife® is concentrated through a proprietary manufacturing process, which concentrates the full spectrum of active constituents in maca over ten times higher than what is found in normal raw maca, and maximizes the bioavailability increasing water solubility from 68% in raw maca to 99% in MacaLife®.
With five years of research, including human double-blind placebo controlled clinical trials, pharmacology and toxicology, FemmenessencePRO PERI has the highest success rate and strongest results of any natural product in the menopause category.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Maca-GO White Paper – Clinical Effects of a Proprietary, Standardized, Concentrated, Organic Lepidium Peruvianum Formulation (Maca-GO) as an Alternative to HRT by Ronald Carter, M.D.
Pre-Gelatinised Maca (Maca-GO) (Lepidium peruvianum Chacon) As Non-Hormonal Herbal Remedy to Reduce Menopausal Symptoms In Pre- And Post-Menopausal Women.
Basic Clinical Pharmacology and Toxicology. Vol. 97, Supp l (1): 48.
Therapeutic effect of Lepidium peruvianum Chacon (Maca-GO) used as a non-hormonal alternative to HRT in Peri-menopausal women.
International Journal of Biomedical Science 2006: Vol. 2, No. 2. 143.
Short and Long-Term Physiological Responses of Male and Female Rats to Two Dietary levels of Pre-Gelatinized Maca (Maca-GO) (Lepidium peruvianum Chacon).
International Journal of Biomedical Science. 1 (2): 13-28.
Hormone-balancing Effect of Pre-Gelatinized Organic Maca (Maca-GO) (Lepidium peruvianum Chacon: (Part I.) Biochemical and Pharmacodynamic Study on Maca using Clinical Laboratory Model on Ovariectomized Rats.
International Journal of Biomedical Science 2006: Vol. 2, No. 3. 100.
Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (Maca-GO) (Lepidium peruvianum Chacon): (II) Physiological & symptomatic responses of early-postmenopausal women to standardized doses of Maca in Double Blind, Randomized, Placebo-Controlled, Multi-Centre Clinical Study.
International Journal of Biomedical Science, Dec. 2006: vol. 2 no. 4, 360 – 374.
Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (Maca-GO) (Lepidium peruvianum Chacon): (III) Clinical responses of early-postmenopausal women to Maca in double blind, randomized, Placebo-controlled, crossover configuration, outpatient study.
International Journal of Biomedical Science., Dec. 2006: vol. 2 no. 4, 375 – 394.